What LEXEO Therapeutics does

LEXEO Therapeutics is a clinical-stage genetic medicine company developing AAV-based gene therapies for genetically defined cardiovascular and central nervous system diseases, founded in 2020 and headquartered in New York (NASDAQ: LXEO). The pipeline is anchored by a proprietary AAVrh.10 capsid delivery platform paired with a scalable Sf9-baculovirus suspension manufacturing process (scaled from 10L to 200L), and is organized into two therapeutic pillars. The cardiac pillar includes lead asset LX2006 (AAVrh.10hFXN for Friedreich ataxia cardiomyopathy, Phase 1/2 with pivotal SUNRISE-FA 2 protocol finalized), LX2020 (AAVrh.10hPKP2 for PKP2-associated arrhythmogenic cardiomyopathy, Phase 1/2), and preclinical LX2021 (Cx43 for desmoplakin cardiomyopathy) and LX2022 (TNNI3 for hypertrophic cardiomyopathy). The CNS pillar comprises LX1001 (APOE2 in Phase 1/2 for APOE4 homozygous Alzheimer's), and preclinical LX1020 and LX1021 (APOE2 with APOE4 miRNA suppression and Christchurch-modified APOE2, respectively). The lead asset has accumulated FDA Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations plus EU Orphan Medicinal Product status; LX2020 holds Orphan Drug and Fast Track; LX1001 holds Fast Track.

The company generates no product revenue and is funded primarily through equity financings and strategic partner capital. Cumulative disclosed funding exceeds $548M since 2021, including a $100M Series B (2021), a Sarepta Therapeutics strategic investment (2023), a $95M PIPE (March 2024), an $80M PIPE (May 2025), a $40M round (June 2025), and a $153.8M public offering with concurrent private placement (October 2025), with stated runway into 2028. Strategic research collaborations include Johnson & Johnson/Abiomed for Impella-based cardiac AAV delivery (January 2026), BioAgilytix Labs for the FDA Breakthrough Device-designated anti-AAV antibody assay, and the co-founded Myoventive, Inc. (June 2025) for next-generation cardiac precision medicines. The company sponsors the CLARITY-FA natural history study to serve as an external control arm for SUNRISE-FA 2.

LEXEO is led by CEO R. Nolan Townsend (former President of Pfizer Rare Disease), with founder Ronald Crystal, MD (Weill Cornell Department of Genetic Medicine) as Chief Scientific Adviser, and Chairman Steven Altschuler, MD (former Spark Therapeutics board chair). Future revenue, when it materializes, will follow a one-time specialty rare-disease pricing model per patient, distributed through specialty rare-disease channels and academic medical centers; no commercial product is approved today.

Name

LEXEO Therapeutics

Legal name

Lexeo Therapeutics, Inc.

Website

https://lexeotx.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

LEXEO Therapeutics is a clinical-stage gene therapy company developing AAVrh.10-based treatments for genetically defined cardiovascular and CNS diseases, including Friedreich ataxia cardiomyopathy, arrhythmogenic and other cardiomyopathies, and APOE4-associated Alzheimer's disease.

Ownership category

akta.pro rank

Product category

Genetic medicines / AAV gene therapy biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Neurology/CNS Gene Therapies (HLAAACAH), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Gene therapy development
• AAV vector therapeutics
• Cardiovascular gene therapy
• Rare disease treatments
• CNS gene therapy

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D

Revenue model

1. Pre-revenue clinical-stage development: LEXEO is a clinical-stage genetic medicine company with no approved products and no product revenue; future revenue will derive from commercialization of gene therapy candidates for cardiovascular and CNS indications (one-time treatment per patient model, consistent with specialty rare-disease therapeutics).
2. Strategic equity / collaboration income (capital): Capital raised from strategic partners (e.g., Sarepta Therapeutics strategic investment, Johnson & Johnson research collaboration) and equity financings from institutional investors; not a recurring operating revenue stream.

Go-to-market motion3 records

Core offering

LEXEO Therapeutics is a clinical-stage genetic medicine company that develops adeno-associated virus (AAV)-based gene therapies to treat genetically defined cardiovascular and central nervous system diseases. Its pipeline includes lead candidate LX2006 for Friedreich ataxia cardiomyopathy (pivotal SUNRISE-FA 2 trial initiating Q2 2026), plus LX2020 (PKP2-ACM), LX2021 (DSP cardiomyopathy), LX2022 (TNNI3 HCM) in cardiology, and LX1001, LX1020, LX1021 targeting APOE4-associated Alzheimer's disease. All candidates are built on a proprietary AAVrh.10 capsid platform with an optimized Sf9-baculovirus suspension manufacturing process.

Product overview

LEXEO Therapeutics is a clinical-stage genetic medicine company with a portfolio of AAV-based gene therapy candidates organized around two main program pillars: (1) Cardiac programs — LX2006 (Friedreich Ataxia cardiomyopathy, lead asset in Phase 1/2 with SUNRISE-FA 2 pivotal trial initiating), LX2020 (PKP2-ACM, Phase 1/2), LX2021 (DSP cardiomyopathy, preclinical), and LX2022 (TNNI3 HCM, preclinical) — and (2) CNS programs targeting APOE4-associated Alzheimer's disease — LX1001 (Phase 1/2), LX1020, and LX1021. All candidates are built on the company's proprietary AAVrh10 vector delivery platform supported by an Sf9-baculovirus manufacturing process. LEXEO also conducts the CLARITY-FA natural history study (to serve as external control for LX2006) and the HEROIC-PKP2 clinical trial for LX2020. The company retains exclusive worldwide development and commercialization rights to all candidates and pursues both internal development and research collaborations (e.g., Johnson & Johnson for cardiac delivery, BioAgilytix for anti-AAV antibody assay).

Differentiator

Problem solved

Functional benefit

Brands

• LEXEO: Corporate trade name used interchangeably with Lexeo Therapeutics across investor relations, clinical trials website, and corporate communications.

Products and services

• LX2006 AAV-based gene therapy candidate (AAVrh.10hFXN) designed to deliver a functional frataxin (FXN) gene to myocardial cells to treat Friedreich ataxia (FA) cardiomyopathy, restoring mitochondrial function and energy production in cardiac myocytes. Lead clinical-stage asset with FDA Breakthrough Therapy, RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations plus EU Orphan Medicinal Product designation.
• LX2020 AAV-based gene therapy (AAVrh.10hPKP2) designed to intravenously deliver a fully functional PKP2 gene to cardiac muscle for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Granted FDA Orphan Drug and Fast Track designations; evaluated in the HEROIC-PKP2 Phase I/II trial.
• LX2021 Gene therapy candidate designed to deliver functional connexin 43 (Cx43) protein for a group of inherited cardiac muscle disorders including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. Initially targeting Desmoplakin (DSP) cardiomyopathy.
• LX2022 Gene therapy candidate designed to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy (HCM) due to mutations in the TNNI3 gene, accounting for approximately 5% of all HCM cases.
• LX1001 AAV-based gene therapy candidate designed to express the protective APOE2 protein in the CNS of APOE4 homozygous patients to halt or slow the progression of Alzheimer's disease. Granted FDA Fast Track designation; evaluated in the LEAD Phase 1/2 clinical trial.
• LX1020 Gene therapy candidate designed to express the protective APOE2 protein in the CNS of APOE4 homozygous patients while concurrently delivering miRNA to suppress APOE4 expression, achieving conversion to APOE4/E2 heterozygous profile.
• LX1021 Gene therapy candidate designed to express the Christchurch-modified APOE2 protein in the CNS of APOE4 homozygous patients; the Christchurch mutation has been observed to protect patients against Alzheimer's disease even in the presence of significant amyloid pathology.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability10 records

Feature7 records

Recent moves7 records

Expansion highlights8 records

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lexeo-therapeutics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries2 records

Funding overview

Funding rounds7 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LEXEO Therapeutics